Gland Pharma: Gland Pharma Receives Approval for Methylprednisolone Acetate Injectable Suspension USP, Single-Dose and…
Gland Pharma (GLAND) filed a disclosure titled "Gland Pharma Receives Approval for Methylprednisolone Acetate Injectable Suspension USP, Single-Dose and Multiple-Dose Vials". The company is valued at about ₹50,587 crore.
What happened
Gland Pharma (GLAND) filed a disclosure with the exchanges on 3 November 2026 at 11:28 AM titled "Gland Pharma Receives Approval for Methylprednisolone Acetate Injectable Suspension USP, Single-Dose and Multiple-Dose Vials".
Company snapshot
Gland Pharma is a mid-cap company in the Healthcare sector, with a market value of about ₹50,587 crore.
The stock last traded at ₹3,066.6, against a 52-week range of ₹1,573.6–₹3,171 (3.3% below the high).
Before this filing the shares had moved +3.5% over the month and +23.7% over three months. Average daily turnover over the last 20 sessions was about ₹118 crore.
Promoters held 51.77% at the end of Q1 FY27, down 0.06% points from the previous quarter. Foreign institutions owned 8.74% and domestic institutions 30.44%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,506 | 215.5 | 13.08 |
| Q2 FY26 | 1,487 | 183.7 | 11.15 |
| Q3 FY26 | 1,695 | 261.5 | 15.87 |
| Q4 FY26 | 1,743 | 366.7 | 22.26 |
| Q1 FY27 | 1,800 | 317 | 19.23 |
What history shows
This is not the company's first regulatory disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 1.0% on average the next trading day and was down 5.9% on average after five days (2 filings with price data).
Across 170 similar disclosures by other Healthcare companies, shares moved +0.5% on average the next day and +1.7% over five days; 48% of them rose the next day.
Market-wide, 5,571 regulatory filings with an impact score of 50 or more saw an average next-day move of +0.3%, with 49% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 23 Oct 2026 | Conclusion of USFDA Unannounced Inspection at Company's Formulation… | +4.7% | — |
| 16 Jul 2026 | Action(s) taken or orders passed | −2.8% | −5.9% |
What to watch
- 6 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- U.S. FDA issues four observations to Gland Pharma formulation facility near Hyderabad
- Gland Pharma Ltd. Estimates – NSE:GLAND
- Gland Pharma names Ajay Sahni CEO of Singapore subsidiary
- Gland Pharma Appoints Ajay Sahni as CEO of Singapore-Based International Subsidiary
- Did Gland Pharma's 77% Run Pass You By? What Bulls Still Need
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.